Identification of Inhibitors of Drug-Resistant Candida albicans Strains from a Library of Bicyclic Peptidomimetic Compounds
摘要:
The screening of a library of small molecule peptidomimetics toward secreted aspartic proteinase-2 (SAP2) of Candida aibicans allowed us to identify two compounds that showed in vitro inhibitory potency comparable to pepstatin A. In an experimental model of vaginal candidiasis, the two candidate compounds were as active as a therapeutic dose of fluconazole. Importantly, this activity was fully preserved when the challenger was a fluconazole-resistant strain of the fungus. Altogether, our data demonstrate SAP2 as a valid C. albicans target for the development of new drugs against this important human pathogen.
Bicyclic peptidomimetic inhibitors of aspartyl-proteases for the treatment of infectious diseases
申请人:Universita' Degli Studi di Firenze
公开号:EP2189462B9
公开(公告)日:2012-06-13
Bicyclic peptidomimetics targeting secreted aspartic protease 2 (SAP2) from Candida albicans reveal a constrained inhibitory chemotype
作者:Chiara Calugi、Andrea Trabocchi、Flavia De Bernardis、Silvia Arancia、Pierluigi Navarra、Roberto Cauda、Antonio Cassone、Antonio Guarna
DOI:10.1016/j.bmc.2012.09.031
日期:2012.12
The in vitro screening of stereoisomeric bicyclic peptidomimetics towards SAP2 of Candida albicans revealed a constrained chemotype as aspartic protease inhibitor in the micromolar to nanomolar range. The results indicated that the acetal bridge may serve as a transition-state isostere, and that the right match between interactions with subsites and the orientation by hydrogen bonding with Gly85 is the main requisite for inhibitory activity. Molecular docking calculations suggested the bicyclic acetal scaffold to be capable of interacting with the two catalytic aspartic acids, thus resulting in good inhibitory activity with only two hydrophobic groups addressing the enzyme catalytic subsites. (C) 2012 Elsevier Ltd. All rights reserved.